Scholar Rock Holding Corp (SRRK) Wednesday reported positive results from the Phase 2 EMBRAZE study of apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.
The EMBRAZE study was designed to evaluate apitegromab in adults with obesity while receiving tirzepatide. In the study, patients receiving apitegromab with tirzepatide showed a 54.9% preservation of lean mass compared to those who received tirzepatide alone. Patients who received apitegramab with tirsepatide lost 18.8 pounds of fat over 24 weeks, compared to 17.7 pounds of fat loss in those who received tirsepatide alone. Further, Apitegromab with tirzepatide was generally well tolerated by participants.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.